2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Imaging, Omics Technologies, Serologic Tests, Bioinformatics, Profiling, Treatment Considerations, Supportive Care, Therapy Sequence, Biological Therapies, (CAR)-T Cell Therapies, Immunotherapy, Non-Biological Therapies, Chemotherapy, Women’s Health, Biological Processes, Apoptosis, Immune Mechanism, Molecular Biology, Clinical Practice (Health Services and Quality), Patient Safety, Quality Improvement, Quality of Care, Diseases, Bone Marrow Failure Syndromes, Genetic Disorders, Immunology, Immunodeficiency, White Blood Cell Disorders, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Indolent Lymphoma, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Survivorship, Study Population, Human, Animal Model
PAPER

2981 Serum vascular endothelial growth factor (VEGF) monitoring in idiopathic multicentric castleman disease

Anan Li, MD, Zihan Yang, MD2, Yu-han Gao, PhD3, Yue Dang4, Haoyi Xu5, Hong-yi Wang6, Lu Zhang, M.D.7, Jian Li, MD8
1 Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
2 Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
3 Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
4 Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
5 Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
6 Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
7 Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
8 Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

Objective: Idiopathic multicentric Castleman disease (iMCD) is a rare lymphoproliferative disorder characterized by a systemic cytokine storm. Vascular endothelial growth factor (VEGF) plays a crucial role in the pathogenesis of iMCD as a downstream effector in the interleukin-6 (IL-6) signaling pathway. However, its clinical value for disease monitoring requires further elucidation.

Methods: This study retrospectively evaluated 363 serum VEGF measurements (277 Flare, 31 PR, and 54 CR samples) from 246 iMCD patients. Among the cohort, 139 patients had baseline VEGF data available at the time of diagnosis. We analyzed the patients' baseline characteristics and the correlation between VEGF levels and disease activity.

Results: Baseline VEGF levels differed by clinical subtypes but not histopathology. VEGF levels were significantly higher in patients with TAFRO and IPL subtypes compared to the NOS subtype (median [interquartile range]: 1307 [525-2316] vs. 1687 [903-2596.25] vs. 696 [420.75-1525.75] pg/mL, p=0.019). No significant differences were observed among pathological subtypes (p=0.54). Disease severity also impacted these measurements, with severe iMCD cases presenting significantly elevated VEGF compared to non-severe cases (1385 [561.5-2796] vs. 979 [429.25-1704] pg/mL, p=0.039). Baseline serum VEGF correlated positively with platelet count (R=0.18, p=0.038) and C-reactive protein (CRP) (R=0.17, p=0.045), but not with IL-6 levels (R=0.038, p=0.67). VEGF levels were closely tracked with disease activity: patients in the flare phase had significantly higher VEGF levels (979 [377-2066] pg/mL) than those in complete remission (345 [184.75-575.25] pg/mL, p<0.0001) and partial remission (355 [256.5-783.5] pg/mL, p=0.0044). Correspondingly, serum VEGF levels decreased significantly in response to treatment in the paired sample analysis (p<0.0001).

Conclusions: Serum VEGF levels effectively reflect clinical phenotypic variations and disease severity in iMCD, serving as a disease evaluation marker independent of IL-6. Notably, patients with iMCD-TAFRO also exhibit significant VEGF elevation; therefore, this marker should not be used as a criterion to differentiate TAFRO from POEMS syndrome. Serum VEGF serves as a valuable clinical tool for monitoring disease activity in patients with iMCD.

Anan Li, MD: No relevant conflicts of interest to declare.